African Genomics on the Global Stage: AACR 2026
This year, Yemaachi Biotech was proud to participate in the American Association for Cancer Research (AACR) Annual Meeting in San Diego, one of the world’s largest and most influential cancer research conferences. AACR brings together leading researchers, clinicians, pharmaceutical companies, biotechnology innovators, and policymakers from across the globe to share breakthroughs that are shaping the […]
Cancer Care Now Runs on Data Infrastructure
Why the Future of Oncology Depends on More Than Medicine By David Hutchful When most people think about advances in cancer care, they think about new drugs, new therapies, or breakthrough discoveries in biology. But increasingly, one of the most important determinants of progress in oncology is something far less visible: data infrastructure. Modern cancer […]
FFPE Tissue: A Goldmine for Cancer Genomics Research
By Joyce Ngoi, Max Nwuba & Elikem Kisser Cancer samples collected in the form of Formalin-fixed paraffin-embedded (FFPE) tissue are most often the primary source for the characterisation of tumours. FFPE specimens are routinely obtained from patients during biopsies or surgical resections and preserved for long-term clinical diagnosis and research, making FFPE the gold standard […]
OneBio Venture Studio Makes Second Investment Into Yemaachi Biotech
OneBio Venture Studio is proud to announce its second investment from Fund II into Yemaachi Biotech, a Ghana-based genomics company building the world’s most diverse cancer bio-database to develop next-generation cancer drugs that work across diverse populations. Yemaachi Biotech‘s work is rooted in a simple but powerful conviction: precision oncology research, diagnostics, and therapeutics must […]
2026 Pediatric Oncology Yvonne Award by OncoDaily
Emmanuella Amoako, MD, MWACP, FGCP, was honored with the Pediatric Oncology Yvonne Award during the Yvonne Awards Ceremony at OncoDaily Party 2026, held on May 29 at Park West in Chicago. Natera was the exclusive partner of the Yvonne Awards Ceremony and OncoDaily Reception. The recognition highlights Dr. Amoako’s work as a pediatric oncologist, clinical researcher, global health advocate, and leader in childhood […]
Early lessons from the implementation of a pan-African clinico-genomic cancer platform: The African Cancer Atlas
Abstract Background: Limited representation of African populations in cancer genomics constrains the clinical applicability of precision oncology. We describe the establishment and early outcomes of The African Cancer Atlas (TACA), a multi-site platform integrating genomics, harmonized clinical data, and community engagement for adult breast cancer research across Africa. Methods: TACA, led by Yemaachi Biotech, has so far […]
Determinants of triple‑negative breast cancer among African patients: Early results from The African Cancer Atlas
Abstract Background: Triple‑negative breast cancer (TNBC) is disproportionately common among women of African ancestry and is associated with aggressive clinical behavior and limited therapeutic options. Understanding demographic and contextual determinants of TNBC across African countries is essential to improving prevention, early detection, and precision oncology strategies. Using harmonized data from The African Cancer Atlas (TACA)–an […]
Biotech Bravado: What This Entrepreneur Is Pioneering In Africa – Forbes Africa.
At the laboratory of a genomics research company headquartered in Ghana’s capital Accra, the low, steady whir of a whole-genome sequencer, calibrated to read the most intimate instructions of human life, is helping process cancer samples collected thousands of miles away, from across Africa. “Sequencing is ongoing… We recruited over 300 people last year. So, […]
Yaw Bediako Recognized Among The 100 Most Influential CEOs in Oncology in 2025.
Yaw Bediako is an immunologist and the CEO of Yemaachi Biotech, an Accra-based immunogenomics company focused on diversifying precision oncology. Under his leadership, Yemaachi has positioned itself as a key contributor to African cancer research by leveraging the continent’s genetic diversity to identify novel biomarkers and therapeutic targets. A landmark achievement of his tenure is the 2025 launch […]